GxP AI Software 2026: A Complete Technical Buyer's Guide

What GxP AI software actually needs to do

• Generate regulated-grade outputs — validation documents, clinical narratives, risk assessments — that are accurate enough to hand to a human reviewer, not a starting prompt.
• Operate under human-in-the-loop control with enforceable segregation of duties. The AI drafts; a qualified human reviews, approves, and signs. Not optional. See Human-in-the-Loop reviews.
• Maintain a tamper-evident audit trail that captures what the AI generated, who reviewed it, what changes the reviewer made, and who approved the result. See Audit Readiness.
• Publish its own AI governance documentation — model card, benchmark set, guardrails, HITL policy, drift monitoring, fallback — as required by EU Annex 22. See Annex 22 assurance.
• Be validated itself under GAMP 5, with a validation package the customer can inspect and a change control process for AI model updates.

The five categories of GxP AI software

Validation AI — platforms that draft GAMP 5 validation packages, manage V-model deliverables, risk-score requirements, and generate test cases. GxP Copilot is the primary example. These are Category 4 or 5 under GAMP 5 depending on customisation.

Clinical documentation AI — platforms that draft CSRs, safety narratives, protocols, and regulatory submissions from clinical data. TraceDraft is an example. High-criticality category because errors reach regulators.

Quality management AI — AI layered onto eQMS platforms to assist with CAPA root cause analysis, deviation classification, and change impact assessment. See eQMS implementation.

Pharmacovigilance AI — platforms that assist with case processing, narrative generation, and signal detection. See pharmacovigilance.

Regulatory intelligence AI — tools that monitor regulatory guidance, classify submissions, and assist with dossier assembly. See RIM implementation.

The Annex 22 evaluation checklist

• Does the vendor publish a model card — what AI is used, what it was trained on, what it is and is not approved for?
• Is there a published benchmark set — a frozen, versioned evaluation that gates every model release?
• Are there deterministic guardrails that constrain what the AI can output — format, length, permissible content?
• Is the HITL policy documented and enforced by the workflow, not just by policy? Can an author approve their own AI draft?
• Is there a drift monitoring programme — how does the vendor detect when model behaviour changes?
• Is there a documented fallback — does the product keep working when the AI is offline or unavailable?

The Part 11 evaluation checklist

• Do electronic signatures on AI-assisted outputs include re-authentication, meaning, signer name, timestamp, and content binding?
• Is the audit trail tamper-evident at the data layer, not just append-only at the application layer?
• Can authors approve their own drafts — if yes, this is a segregation of duties failure under §11.10(d)?
• Are signed versions frozen — can a signed document be silently edited after approval?
• Is the audit trail independently verifiable without the application — hash-chained or otherwise cryptographically provable?

What to ask in a vendor evaluation

• Show me the Annex 22 documentation package — not a roadmap, the current published version.
• Walk me through how a change to your AI model is change-controlled, tested, and communicated to customers.
• What is your GAMP 5 classification and can I see your validation package?
• What happens if your AI generates something incorrect — how is that detected, flagged, and corrected in the audit trail?
• What is the performance of your AI on a domain-specific benchmark — not general LLM benchmarks, but on life sciences validation or clinical writing tasks?

The total cost of GxP AI software ownership

The purchase price of GxP AI software is rarely the dominant cost. The dominant costs are: the customer-side validation effort (validating the platform in your environment under GAMP 5), the training and change management effort (getting QA, validation, and clinical writing teams to use the AI effectively), and the ongoing oversight effort (reviewing AI outputs, managing AI model updates under change control, and maintaining the Annex 22 assurance stack). Vendors who make the customer-side validation simple — by providing an IQ/OQ protocol, pre-written test cases, and a validation support service — reduce total cost of ownership significantly. Our GxP Copilot customers receive a validation package with their subscription. See book a demo.